Abstract
Drug-resistant tuberculosis (TB) is a major public health concern and contributes to high morbidity and mortality. New evidence supports the use of shorter duration, all-oral regimens, which represent an encouraging treatment strategy for drug-resistant TB. As a result, the landscape of drug-resistant TB pharmacotherapy has drastically evolved regarding treatment principles and preferred agents. This narrative review focuses on the key updates of drug-resistant TB treatment, including the use of short-duration all-oral regimens, while calling attention to current gaps in knowledge that may be addressed in future observational studies.
| Original language | English |
|---|---|
| Pages (from-to) | 268-282 |
| Number of pages | 15 |
| Journal | Pharmacotherapy |
| Volume | 44 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jan 25 2024 |
Bibliographical note
© 2024 Pharmacotherapy Publications, Inc.Funding
DJH, AA, NR, and MT have no relevant conflicts of interest. TM is currently receiving grant funding through Stellus Rx and has participated in scientific advisory boards for AbbVie Inc. and Basilea Pharmaceutica.
ASJC Scopus Subject Areas
- Pharmacology (medical)
Keywords
- multidrug-resistant
- Mycobacterium tuberculosis
- pharmacotherapy
- Humans
- Lung
- Antitubercular Agents/pharmacology
- Tuberculosis, Multidrug-Resistant/drug therapy
Disciplines
- Medical Pharmacology
Fingerprint
Dive into the research topics of 'Updates in pulmonary drug-resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS